Signal Gene-editing cargo crossed the blood-brain barrier in 2025 and a $1.5 billion pact followed

Summary

The chapter pairs a 2025 demonstration of exosomes carrying gene-editing tools across the blood-brain barrier into neurons without an immune response, which it calls a leap for Alzheimer's, Parkinson's and glioblastoma research, with a $1.5 billion collaboration between Eli Lilly and Evox Therapeutics as evidence of industry commitment.